BRANDL TALOS advises International VC Syndicate on Investment in Allcyte

Press release • Corporate Law & Transactions from Roman Rericha, Stephan Strass

BRANDL TALOS advised an international syndicate of venture capital funds, including 42CAP (alongside SMP – Frederik Gärtner) and Amino Collective (both Germany), PUSH Ventures (Austria), Air Street Capital (UK) and VP Venture Partners (Switzerland), on their investment in Allcyte GmbH, an Austrian biotech firm focused on functional drug testing in primary human material.

Allcyte is a three-year old company based in Vienna that aims at revolutionizing cancer treatment by using artificial intelligence and rapid lab tests. The company already has partnerships with some of the largest pharmaceutical companies, including German pharma giant Boehringer Ingelheim.

The BRANDL TALOS team was led by partner Roman Rericha and attorney Stephan Strass and further consisted of senior associate Sonam Schima and associate Elena Ciresa.

The company was advised by Herbst Kinsky (Philipp Kinsky, Carl Walderdorff).

» This investment will enable Allcyte – a biotech firm with great potential – to grow and significantly expand its activities. We are excited that once again a syndicate of renowned venture capitalist funds has trusted our expertise in this investment round. «
Roman Rericha, partner at BRANDL TALOS
The team
Roman Rericha
Partner / Fund Formation, Venture Capital & Start Ups, Corporate Law & Transactions
Roman represents clients in complex cross-border M&A and private equity transactions. Austrian and international venture capital funds regularly turn to him for assisting with investments in Austria. His expert advice also guides start-ups through large-scale financing rounds.

University of Vienna, Faculty of Law (Mag. iur. 2005),
Faculty of Business, Economics and Statistics, (Mag. rer.soc.oec. 2007)
Stephan Strass
Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience
Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)